Aethlon Medical reports Q1 FY2027 results; cash $4.9M, raises $4M post-quarter

AETHLON MEDICAL INC

Cash and cash equivalents ~$4.9M as of June 30, 2026; raised ~$4.0M gross in public offering after quarter-end.
Operating expenses decreased 11.9% to ~$1.6M vs $1.8M in prior-year quarter.
First participant dosed in third/final cohort of Phase 1 oncology study in Australia; early biomarker signals support Hemopurifier.
Long COVID manuscript accepted for publication in International Journal of Molecular Sciences.
Company believes cash resources sufficient to fund operations for at least next 12 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.